Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting now · Phase 3

Conditions studied: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma

In brief

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Key facts

Study ID

NCT07562152

Run by

Immuneering Corporation

People needed

510

Starts

2026-06-05

Expected to finish

2029-02-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be ≥18 years of age
• Must have confirmed diagnosis according to AJCC staging as follows:
• Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Participants must be treatment naive as follows:
• First-line PDAC participants will have received no previous systemic anti-cancer therapy
• Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
• Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values

You may not qualify if…

• Inability to swallow oral medications
• Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
• Participants with only locally advanced disease
• Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Where it is running

• Texas Oncology - San Antonio — San Antonio, Texas, United States (enrolling)
• Texas Oncology Gulf Coast — Webster, Texas, United States (enrolling)
• Blue Ridge Cancer Care — Blacksburg, Virginia, United States (enrolling)
• Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
• City of Hope — Phoenix, Arizona, United States (enrolling)
• City of Hope — Duarte, California, United States (enrolling)
• Poudre Valley Health Care, Inc — Fort Collins, Colorado, United States (enrolling)
• Medical Oncology Hematology Consultants — Newark, Delaware, United States (enrolling)
• Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida, United States (enrolling)
• Florida Cancer Specialists - South — Sarasota, Florida, United States (enrolling)
• Florida Cancer Specialists - North — St. Petersburg, Florida, United States (enrolling)
• Florida Cancer Specialists - East — West Palm Beach, Florida, United States (enrolling)
• Piedmont Healthcare — Atlanta, Georgia, United States (enrolling)
• Illinois Cancer Specialists — Arlington Heights, Illinois, United States (enrolling)
• City of Hope — Chicago, Illinois, United States (enrolling)
• OSF Medical Center — Peoria, Illinois, United States (enrolling)
• Maryland Oncology — Columbia, Maryland, United States (enrolling)
• Missouri Cancer Associates — Columbia, Missouri, United States (enrolling)
• Comprehensive Cancer Centers — Las Vegas, Nevada, United States (enrolling)
• Regional Cancer Care — Belleville, New Jersey, United States (enrolling)
• NYU Langone Health — New York, New York, United States (enrolling)
• Taylor Cancer Research Center — Maumee, Ohio, United States (enrolling)
• Willamette Valley Cancer Institute — Eugene, Oregon, United States (enrolling)
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
• West Cancer Center — Germantown, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.